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Abstract
Introduction: The Ebola virus disease (EVD) outbreak in 2014–2016 in West Africa was the largest on record and
provided an opportunity for large clinical trials and accelerated efforts to develop an effective and safe preventative
vaccine. Multiple questions regarding the safety, immunogenicity, and efficacy of EVD vaccines remain unanswered.
To address these gaps in the evidence base, the Partnership for Research on Ebola Vaccines (PREVAC) trial was
designed. This paper describes the design, methods, and baseline results of the PREVAC trial and discusses
challenges that led to different protocol amendments.
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Methods: This is a randomized, double-blind, placebo-controlled phase 2 clinical trial of three vaccine strategies
against the Ebola virus in healthy volunteers 1 year of age and above. The three vaccine strategies being studied
are the rVSVΔG-ZEBOV-GP vaccine, with and without a booster dose at 56 days, and the Ad26.ZEBOV,MVA-FN-Filo
vaccine regimen with Ad26.ZEBOV given as the first dose and the MVA-FN-Filo vaccination given 56 days later.
There have been 4 versions of the protocol with those enrolled in Version 4.0 comprising the primary analysis
cohort. The primary endpoint is based on the antibody titer against the Ebola virus surface glycoprotein measured
12 months following the final injection.
Results: From April 2017 to December 2018, a total of 5002 volunteers were screened and 4789 enrolled.
Participants were enrolled at 6 sites in four countries (Guinea, Liberia, Sierra Leone, and Mali). Of the 4789
participants, 2560 (53%) were adults and 2229 (47%) were children. Those < 18 years of age included 549 (12%)
aged 1 to 4 years, 750 (16%) 5 to 11 years, and 930 (19%) aged 12–17 years. At baseline, the median (25th, 75th
percentile) antibody titer to Ebola virus glycoprotein for 1090 participants was 72 (50, 116) EU/mL.
Discussion: The PREVAC trial is evaluating—placebo-controlled—two promising Ebola candidate vaccines in
advanced stages of development. The results will address unanswered questions related to short- and long-term
safety and immunogenicity for three vaccine strategies in adults and children.
Trial registration: ClinicalTrials.gov NCT02876328. Registered on 23 August 2016.
Keywords: Ebola, Vaccine, Clinical trials, Protocol, Randomized controlled trials
Introduction
The Ebola virus disease (EVD) outbreak in 2014–2016
in West Africa was the largest since the discovery of the
virus in 1976 with more than 28,000 confirmed cases of
EVD and 11,000 deaths in Guinea, Liberia, and Sierra
Leone (ref: WHO Ebola situation report 2016). The
West-African outbreak prompted the rapid clinical
evaluation of vaccine and therapeutic candidates that
were in early development. As evidenced by the ongoing
Ebola outbreak in the Democratic Republic of Congo
(DRC) ongoing since August 2018, along with other
public health measures, efforts to develop an effective
and safe vaccine against Ebola virus disease must con-
tinue [1].
By the end of 2015, new cases of EVD in West Africa
had dramatically decreased. An open-label, cluster-
randomized, ring vaccination trial conducted in Guinea,
the “Ebola ca suffit” trial, randomized contacts and con-
tacts of contacts to receive the Merck/New Link
rVSVΔG-ZEBOV-GP vaccine immediately after
randomization or 21 days later. There were no cases of
Ebola virus disease 10 days or more following vaccin-
ation among 2108 contacts and contacts of contacts who
were vaccinated immediately compared to 10 such cases
in 1429 contacts and contacts of contacts who initially
consented to receive vaccination 21 days after
randomization [2]. In that trial, which was conducted
mainly in adults, no EVD events occurred more than 10
days after vaccination. Based upon these and other data
this vaccine has been approved by the European Medi-
cines Agency (EMA) and the U.S. Food and Drug Ad-
ministration (FDA) for the prevention of Ebola virus
disease in individuals 18 years of age and older. No im-
munogenicity and limited safety data were collected in
the “Ebola ca suffit” trial, especially in children. Two
other vaccine strategies, the single-dose GlaxoSmithK-
line (GSK) ChAd3-EBO Z (replication-deficient Chim-
panzee adenovirus type 3-derived vector encoding the
Ebola virus Zaire [EBO Z] GP) vaccine and the Johnson
& Johnson (J&J) 2-dose heterologous vaccination regi-
men, Ad26.ZEBOV,MVA-FN-Filo, have completed
phase 2 testing. The heterologous two-dose Ad.26.ZE-
BOV,MVA-BN-Filo vaccine regimen has shown an ac-
ceptable safety profile and was well-tolerated and
immunogenic in healthy 18–50 year-old adults volun-
teers from France and England [3, 4] and Africa coun-
tries [5, 6]. Data on safety, tolerability, and
immunogenicity from multiple studies supported the
European marketing authorization for this Ebola two-
dose heterologous vaccine regimen granted by the
European Commission after assessment by European
Medical Agency in July 2020 for the prevention of Ebola
virus disease caused by the Zaire ebolavirus species in
individuals aged one year and above. In addition, safety
and immunogenicity up to 12 months after vaccination
of the rVSVΔG-ZEBOV-GP and ChAd3-EBO Z vaccine
have been evaluated in a phase 2, placebo-controlled
trial of adults in Liberia (Partnership for Research on
Ebola Virus in Liberia I [PREVAIL I]) [7]. The planned
phase 3 component of PREVAIL I could not be com-
pleted because of the decline in cases of EVD resulting
from public health efforts.
While there was substantial progress in the develop-
ment of Ebola vaccines during the 2014–2016 West
Badio et al. Trials           (2021) 22:86 Page 2 of 15
African epidemic, multiple questions regarding the safety
and efficacy of EVD vaccines remain unanswered, in-
cluding the durability and the immediacy of immune re-
sponses generated by different vaccine strategies with
and without a booster, and the safety of these Ebola vac-
cines in special populations, particularly children.
To address these gaps, a phase 2 trial, the Partnership
for Research on Ebola Vaccines (PREVAC) trial, was de-
signed and initiated in 2017 to compare three vaccine
strategies with placebo in adults and children in Guinea,
Liberia, Mali, and Sierra Leone.
Methods
Trial design
The PREVAC trial is a randomized, double-blind, super-
iority, placebo-controlled phase II clinical trial evaluating
three vaccine strategies against the Ebola virus.
We have conducted this trial as per the recommenda-
tions for interventional trials (SPIRIT). The final report-
ing of this trial will be in accordance with the
Consolidated Standards of Reporting Trials (CONSORT)
statement.
Trial location
Healthy volunteers were enrolled at 6 sites in four coun-
tries: Guinea at two sites (Landreah located in an urban
area in Conakry and Maferinyah, a rural area in the
Forecariah region), Liberia (Redemption Hospital in
Monrovia), Mali at two sites (Center for Vaccine Devel-
opment (CVD) and the University Clinical Research
Center (UCRC), both in the capital Bamako), and Sierra
Leone (Mambolo, a rural community in Kambia District,
northern Sierra Leone).
Eligibility criteria
Inclusion into the study was based on the following cri-
teria: (1) willingness to participate and sign informed
consent/assent, (2) age ≥ 1 year, (3) planned residency in
the area of the study site for the next 12 months, and (4)
willingness to comply with the protocol requirements.
Participants were excluded from enrolment based on
the following: (1) fever > 38 °C, (2) history of EVD (self-
report), (3) pregnancy (a negative urine pregnancy test
was required for females of child-bearing potential), (4)
positive HIV test for participants < 18 years of age, (5)
reported current breast-feeding, (6) prior vaccination
against Ebola, (7) any vaccination in the past 28 days or
planned within the 28 days after randomization, and (8)
in the judgment of the clinician, any clinically significant
acute/chronic condition that would limit the ability of
the participant to meet the requirements of the study
protocol.
Objectives
The primary aim of the study is to evaluate the durabil-
ity and immediacy of the antibody response to vaccin-
ation. The primary objective of the trial is to compare
each of the three vaccine strategies with the pooled pla-
cebo group (3 pair-wise comparisons) for antibody re-
sponses 12 months after randomization (durability of
response). This will be addressed separately for adults
and children. Other objectives stated in the protocol are
included in Additional file 1: Appendix 1.
For the pharmaceutical companies providing the vac-
cines, information is also being collected to support
regulatory filings.
Interventions
The three vaccine strategies being studied are the
rVSVΔG-ZEBOV-GP vaccine, with and without a
booster dose at 56 days, and the 2-dose heterologous
vaccination regimen Ad26/MVA. One (1) mL from a
3 mL syringe of the rVSVΔG-ZEBOV-GP vaccine
was administered for the prime and booster vaccin-
ation. The Ad26/MVA requires a 0.5-mL administra-
tion of Ad26.ZEBOV from a 3-mL syringe for the
first vaccination dose and second dose vaccination of
MVA-BN-Filo (0.5 mL from a 3-mL syringe) at 56
days.
The 2-dose heterologous vaccination regimen
Ad26.ZEBOV,MVA-BN-Filo (0.5 mL from a 3mL syr-
inge for both doses) is comprised of an Ad26.ZEBOV
vaccine which consists of a single recombinant,
replication-incompetent human Ad26 vector, con-
structed to express the Ebola virus Mayinga GP. The
second dose with MVA-BN-Filo at 56 days encodes the
GP of Sudan virus (SUDV; formerly known as Ebola
Virus Sudan), EBOV (formerly known as Ebola Virus
Zaire), and Marburg Virus (MARV) Musoke and the nu-
cleoprotein of Tai Forest virus (TAFV; formerly known
as Côte d’Ivoire ebolavirus). The Ad26.ZEBOV,MVA-
BN-Filo vaccination regimen was given at the same dose
in versions 2.0, 3.0, and 4.0 of the PREVAC protocol.
Version 1.0 was never implemented.
The rVSVΔG-ZEBOV-GP vaccine is comprised of a
single rVSV isolate (11,481 nt) modified to replace the
gene encoding the VSV G envelope GP with the gene
encoding the envelope GP from ZEBOV (Kikwit, 1995
strain) (1 mL IM administration). The rVSVΔG-ZEBOV-
GP vaccine was not used in Version 2.0. The rVSVΔG-
ZEBOV-GP dose was given as a 2-fold diluted dose (ap-
proximately 5 × 107 plaque-forming units [pfu]/mL) in
Version 3.0 and was given as an undiluted dose (geomet-
ric mean of available assays 9.4 × 107 pfu/mL) in Version
4.0. The doses of rVSVΔG-ZEBOV-GP used in versions
3.0 and 4.0 are referred to as the diluted and undiluted
doses, respectively.
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The placebo is sterile normal saline (sodium chloride
0.9% for injection, United States Pharmacopeia,
preservative-free).
Study setting
Initially, it was envisaged that eligible participants would
be randomized to one of the following five groups in a 2:
1:2:1:1 allocation: (1) Ad26.ZEBOV (prime vaccination
at day 0) (0.5 mL) followed by a second dose with MVA-
BN-Filo (0.5 mL) at 56 days, (2) placebo (at
randomization and at 56 days) (0.5 mL), (3) rVSVΔG-
ZEBOV-GP (prime at day 0) (1 mL) followed by placebo
boost (1 mL) at 56 days, (4) rVSVΔG-ZEBOV-GP (prime
at day 0) (1 mL) followed by rVSVΔGZEBOV-GP
booster dose (1 mL) at 56 days, and (5) normal saline
placebo (prime at day 0 and boost at 56 days) (1 mL)
(Fig. 1). The study design included two placebo groups
because the Ad26.ZEBOV and rVSVΔG-ZEBOV-GP
vaccines were administered at different volumes and
therefore each required a different placebo to match
their specific volume of injection. For the primary ana-
lyses, the two placebo groups will be pooled.
A week prior to the commencement of enrollment for
version 1.0 of the PREVAC trial protocol, an ongoing
open-label study (the PREPARE study; ClinicalTrials.gov
Identifier: NCT02788227) evaluating the safety and im-
munogenicity of the rVSVΔG-ZEBOV-GP vaccine
among healthcare workers in the USA and Canada was
temporary paused because 3 out of the 9 initial partici-
pants who had received the rVSVΔG-ZEBOV-GP
Fig. 1 PREVAC study design for each version of the protocol
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vaccine reported arthritis. A vaccine lot investigation
was undertaken which resulted in no quality findings.
Due to site readiness in both Guinea and Liberia, while
the lot investigation was ongoing, the protocol was re-
vised to version 2.0 to exclude the rVSVΔG-ZEBOV-GP
and matching placebo arm. Thus, the PREVAC trial
commenced with a two-arm strategy and randomized
participants ≥ 12 years of age to the Ad26.ZEBOV first
dose (0.5 mL) followed by an MVA-BN-Filo second dose
(0.5 mL) at 56 days or to matching placebo in a 2:1
randomization ratio (Fig. 1—top panel). Version 2.0
aimed to enroll up to 600 participants to allow migration
quickly to the original five arm randomization.
Even though no quality finding was found in the initial
lot of rVSVΔG-ZEBOV-GP vaccine, a new lot was pre-
pared. Upon review of the certificate of analysis of this
new lot (release potency of 9.4 × 107 pfu/mL), it was de-
cided to initially give the rVSVΔG-ZEBOV-GP vaccine
at a 2-fold dilution (approximately 5 × 107 pfu/mL)
which the study team referred to as the diluted dose. In
June 2017, the protocol was amended and version 3.0 in-
cluded randomization to 5 groups with the rVSVΔG-
ZEBOV-GP vaccine groups being given the diluted dose
(Fig. 1—middle panel). As a safety precaution, enroll-
ment was staggered by age group, starting with children
aged 12–17 and adults. After 70 children aged 12–17
had been enrolled, safety data until day 28 were reviewed
by an independent Data and Safety Monitoring Board
(DSMB), which identified no safety concerns and recom-
mended opening enrollment to children aged 5–11 years.
The procedure was repeated for the 5–11 and 1–4 age
groups. In each age group, a DSMB review was con-
ducted after 70 children were enrolled and followed for
28 days, before enrollment was opened to the next youn-
ger age group. It was decided that once the safety of the
diluted dose of rVSVΔG-ZEBOV-GP had been estab-
lished in children, the trial protocol would be amended
to use the undiluted rVSVΔG-ZEBOV-GP vaccine.
In April 2018, after the safety of all three vaccine strat-
egies, including the diluted dose of rVSVΔG-ZEBOV-
GP, had been determined in each of three age groups of
children (1–4, 5–11, and 12–17 years) by the independ-
ent DSMB, the PREVAC protocol was again amended.
This version of PREVAC (version 4.0) follows the design
originally planned (version 1.0) and that of version 3.0
except that the undiluted dose of the rVSVΔG-ZEBOV-
GP vaccine (9.4 × 107 pfu/mL) was to be used (Fig. 1—
bottom panel). The enrollment targets in version 4.0
were 1400 children aged 1–17 years and 1400 adults.
The investigators of PREVAC agreed that the primary
results would be based on data from version 4.0.
Both versions 2.0 and 3.0 of the study protocols were
implemented in Guinea at Landreah and Maferinyah
sites and at Redemption Hospital in Liberia. Protocol
version 4.0 was implemented in these three sites and
also in the CVC and UCRC sites in Mali and at the
Mambolo site in Sierra Leone.
Randomization and blinding
The randomization groups and allocation ratio for each
version of the protocol are presented in Fig. 1. For each
vaccination center, the randomization schedule was pre-
pared centrally, using block randomization to ensure the
desired allocation ratio for each vaccination center.
Syringes were prepared one by one (whenever a par-
ticipant was ready to be randomized) at the local study
pharmacies by unblinded staff not involved in any other
trial procedure. The syringe content (type of vaccine or
placebo) was defined according to a central list that had
been prepared by the University of Minnesota prior to
the start of the trial, reflecting the above mentioned
specifications for the randomization schedule. Allocation
concealment was achieved by the use of a computer ap-
plication that only revealed the next entry on the list
one by one to the on-site pharmacy staff. The prepared
syringe was labeled with a unique Syringe IDentifier
(SID) and a bar code identifier tear-off label. To ensure
blinding of the remaining site staff and the trial partici-
pants, syringe content was masked by a label covering
the whole syringe. Although it cannot be excluded that
the staff administering the vaccine could distinguish be-
tween the syringes containing 0.5 mL or 1 mL, they did
not know whether the syringe contained active vaccine
or placebo. At the time of vaccination, the tear-off label
on the syringe with the SID was attached to the baseline
case report form (CRF) creating the primary link be-
tween the vaccine administered and the participant iden-
tification (PID). This event is considered the point of
randomization and ensures that all randomized partici-
pants receive an injection, active or placebo. The syrin-
ges for the booster vaccination at day 56 were prepared
at the local pharmacies, filled with an active vaccine or
placebo depending on the participant’s random assign-
ment, and labeled with the PID. The laboratories carry-
ing out the safety and immunogenicity analyses were
blinded to the random assignment. Study participants
and clinical staff assessing the study participants for
safety and laboratory outcomes will remain fully blinded
until all participants from the three protocol versions
have completed 12months of follow-up and results be-
come available. Procedures were put into place to break
the blind if necessitated by a medical emergency. If
unblinding of a participant for safety reasons was re-
quired, it was documented.
Study endpoints
The primary endpoint is the GP-EBOV antibody re-
sponse 12 months after randomization. This is the
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primary endpoint that will be used to compare the im-
munogenicity of the three vaccine strategies with pla-
cebo. Other endpoints are as follows;
 For rVSVΔGZEBOV-GP arms only, GP-EBOV anti-
body response at day 28 after vaccination will be
used for regulatory purposes for comparison to
other studies and for bridging children to adults.
 For the Ad26.ZEBOV,MVA-BN-Filo vaccine arm
only, GP-EBOV antibody response at month 3 after
randomization (approximately 28 days after the sec-
ond dose of vaccine) will be used for regulatory
purposes.
The primary analysis will be performed separately, for
adults and children, and will exclude participants with
elevated antibody titers at baseline.
Antibodies to the Ebola virus GP will be measured
with the Filovirus Animal Nonclinical Group (FANG)
ELISA assay [8]. The precise definition of antibody re-
sponders will be defined prior to unblinding of the study
results. Other assays may also be used. If a correlate of
protection is identified, stored sera will be used to meas-
ure the correlate and carry out comparisons of the three
vaccine strategies with placebo and with one another.
Data collection plan
Time and events schedule for baseline and regularly
scheduled follow-up visits in the PREVAC study is de-
scribed in Table 1. After it had been established that vol-
unteers met the eligibility criteria and informed consent
had been obtained from them or, in the case of children,
a parent or guardian background data were collected.
Demographics and a short medical history were ob-
tained, blood was drawn as specified by the protocol,
and then participants then received their first dose of
the vaccine (“prime vaccination”). Randomization oc-
curred at the point of vaccination as described above.
For 30 min after the vaccination, participants were
watched closely, injection site reactions and targeted
symptoms were assessed, and possible grade 3 or 4 ad-
verse events were recorded.
After the prime vaccination at study entry, initial
follow-up visits occurred at: 7 (± 3 days), 14 (± 3 days),
and 28 (± 7 days) days. The booster dose of vaccine was
administered on day 56 (53 to 66 days) with further
follow-up visits at 63 days (7 ± 3 days after the booster
vaccination), at 3 months (± 14 days), 6 months (± 1
month), and 12months (± 1 month). Visits will continue
at 24 (± 6 month), 36 (± 6 month), 48 (± 6 month), and
60 (− 6 month; + 1 month) months as part of the PREV
AC-UP study. At each follow-up visit up to month 3, in-
jection site reactions, targeted symptoms, and grade 3 or
4 adverse events that occurred since the previous visit
are reported. At all follow-up visits, malaria and serious
adverse events (SAEs) are reported, the temperature is
recorded, and blood is drawn and stored for future im-
munogenicity assessments and other research.
For children, additional data were collected. Blood
chemistries were assessed prior to the prime and booster
vaccination at baseline and day 56 respectively and 7
days after each vaccination. Also, during the first week
following the prime and booster vaccination, daily con-
tacts were made with children to assess injection site re-
actions, targeted symptoms and serious adverse events
(SAEs), and body temperature.
Blood samples are collected at each site and processed
according to their final use. A local laboratory analyzed
blood samples at day 0 for adults and at days 0, 7, and
63 for children and adolescents for blood chemistry and
hematology to assess potential vaccine toxicities. Labora-
tory values are graded for severity according to the Div-
ision of AIDS (DAIDS) Adverse Event Grading tables.
Serology for HIV and syphilis was performed prior to
randomization using rapid tests. If the participant had a
positive HIV or syphilis test, he/she was offered post-
counseling and was referred to a pre-identified health
structure for treatment. All countries use their own nor-
mal ranges as a reference. For Guinea, the Ghana values
from Dooso et al. [9, 10] were used; for Liberia, those
used in PREVAIL 1 [7] were adopted; for Sierra Leone,
they were those used for the EBL3001 trial
(NCT02509494); and for Mali, the normal values used
were those from Khone et al. [11].
The FANG assay to measure the antibody response to
Ebola glycoprotein is performed at the Liberian Institute
for Biomedical Research (LIBR) laboratory in Monrovia
for participants from Guinea and Sierra Leone, at the
UCRC for participants from Mali, and at the NIAID In-
tegrated Research Facility (IRF) (Maryland, USA) for
participants from Liberia. Aliquots are shipped from
sites to the relevant laboratory at regular intervals. Qual-
ity controls for intra- and inter-laboratory reproducibil-
ity are performed on a regular basis. Additional antibody
response testing using a validated FANG assay will be
performed for specific time-points (day 0, day 28, month
3, and month 12) at Quest diagnostics Clinical Labora-
tories Inc., San Juan Capistrano, USA (FOCUS), as part
of the regulatory activities of Merck and JnJ.
A CRF with a unique PID is completed for each par-
ticipant consented and screened. The CRF is an eCRF
developed with Ennov Clinical in English and French.
Due to logistical hurdles, direct electronic data collection
was not an option. Therefore, the clinical data are col-
lected on paper CRF Forms and then entered in the
eCRF the same day. Laboratory results conducted by the
study team are directly extracted for the local Laboratory
information management system and transferred on a
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Table 1 Time and event schedule for baseline and regularly scheduled follow-up visits in the PREVAC study
Events Adults Children
Screening (children must have a documented negative HIV test prior to randomization) X
Baseline
Informed consent/assent X X
Initial vaccination X X
Demographics a) X X
Contact information b) X X
Indicators of increased risk c) X X
Height, weight and temperature X X
Mid-upper arm circumference for children 1–5 years X
Pregnancy test for females of child-bearing potential, i.e., females who have experienced menarche or who are aged 14 years
and older
X X
Blood sample for immunogenicity testing and future research X X
Blood sample for chemistries and CBC X X
Blood sample for HIV/syphilis testing X X
Saliva sample for assessing viral shedding (subsample) X
Stored blood for assessing T cell and memory B cell function in a subset of participants in Guinea X
Injection site reactions, targeted symptoms of any grade severity, and grade 3 or 4 AEs following prime vaccination X X
HIV pre-counseling X X
Days 1 to 6 following prime and booster vaccination
Contact for injection site reactions, targeted symptoms of any grade severity, grade 3 or 4 AEs, measurement of temperature,
and possible SAEs in children
X
Day 7 and day 63
Injection site reactions, targeted symptoms of any grade severity, and grade 3 or 4 AEs X X
Blood sample for immunogenicity testing and future research X X
Saliva sample for assessing viral shedding (subsample) X
Blood sample for assessing T cell and memory B cell function in a subset of adults in Guinea X
HIV and syphilis post-counseling referral X X
Blood sample for chemistries and CBC X
Temperature X X
Day 14
Injection site reactions, targeted symptoms of any grade severity, and grade 3 or 4 AEs X X
Temperature X X
Blood sample for immunogenicity testing and future research X X
Saliva sample for assessing viral shedding (subsample) X
Blood sample for assessing T cell and memory B Cell function in a subset of adults in Guinea X
Day 28
Injection site reactions, targeted symptoms of any grade severity, and grade 3 or 4 AEs X X
Temperature X X
Weight X
Blood sample for immunogenicity testing and future research X X
Saliva sample for assessing viral shedding (subsample) X
Day 56
Booster vaccination X X
Blood sample for immunogenicity testing and future research X X
Pregnancy test for females of childbearing potential, i.e., females who have experienced menarche or who are aged 14 years X X
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daily basis to the centralized data center (EUCLID/
FCRIN Clinical Trials Platform, Inserm/Univ Bordeaux,
France).
Source data verification was done by regular on-site
monitoring under the responsibility of the sponsors on
site to ensure data integrity, and moreover, remote mon-
itoring was done in almost real time to identify trends
and potential problems that go beyond just transcription
problems from source documents.
Sample size and statistical analysis
The sample size for version 4.0 of the protocol was cal-
culated to provide power to compare safety and im-
munogenicity separately for adults (N = 1400) and
children (N = 1400). The sample size is greater than that
which is required to address the primary objectives
because, if a correlate of protection is identified, the vac-
cine strategies will be compared with one another for
that correlate using an intention to treat analysis. Ex-
pected differences between vaccine groups may be
smaller than comparisons with placebo and the correlate
may have greater variability than the assay which will be
used to measure antibody titers to address the primary,
secondary, and exploratory objectives. The larger sample
size will also permit the exploration of subgroups and
preserve power in the event there are more participants
with elevated antibodies at baseline than anticipated.
With a type 1 error = 0.0167 (2-sided) to adjust for the
three comparisons, separately for adults and for children
in all age groups combined, and power = 0.90, even if the
percent with a positive antibody response at 12 months
is 50% in a vaccine group, with equal allocation,




Injection site reactions, targeted symptoms of any grade severity, and grade 3 or 4 AEs following booster vaccination X X
Saliva sample for assessing viral shedding (subsample) X
Blood sample for assessing T cell and memory B cell function in a subset of adults in Guinea X
Day 70
Blood sample for assessing T cell and memory B cell function in a subset of adults in Guinea X
Months 3 and 6
Injection site reactions, targeted symptoms of any grade severity, and grade 3 or 4 AEs (Month 3 only) X X
Temperature X X
Weight X
Mid-upper arm circumference for children 1–5 years X
Blood sample for immunogenicity testing and future research X X
Saliva sample for assessing viral shedding (subsample at month 3 only) X




Mid-upper arm circumference for children 1–5 years X
Blood sample for immunogenicity testing and future research X X
Survey data for the study on barriers and facilitators to PREVAC retention X X
Blood sample for the parasitology assays for the malaria substudy in Sierra Leone and in Guinea (Landreah site) X X
Blood sample for assessing T cell and memory B cell function in a subset of adults in Guinea X
SAEs throughout follow-up X X
EVD events (reported as soon as aware) throughout follow-up and where possible a stored blood sample for future
research
X X
Death (reported as soon as aware) throughout follow-up X X
Pregnancy outcome for women who become pregnant in the first 3 months of follow-up after prime vaccination X X
a)Birth month and year, gender
b)Contact information for self and 2 contacts who will know how to locate the volunteer
c)Role as health care worker, contact with persons known to have EVD
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approximately 30 participants per group (60 participants
in total) are needed assuming the percent in the placebo
group with a positive antibody response is approximately
7%. With unequal allocation as for the rVSVΔG-
ZEBOV-GP with the booster versus placebo comparison,
a total of 63 participants (21 vaccinated with rVSVΔG-
ZEBOV-GP with a boost and 42 vaccinated with pla-
cebo), a difference of 50% versus 7% can also be detected
at 12 months with 87% power. These sample size esti-
mates indicate that power for the planned subgroup ana-
lysis by age is also appropriate.
The planned sample size is also adequate for the com-
parisons with placebo if more than 4% of participants
are antibody positive at baseline and excluded from the
primary analysis and if there are some missing data at
12 months of follow-up.
More information about the statistical analysis of the
PREVAC trial is described in Additional file 1: Appendix
2.
Substudies
There are currently two substudies ongoing and two
planned in PREVAC. The immunological substudy is be-
ing conducted in Guinea with the primary objective of
evaluating the T cell responses induced by the two vac-
cines candidates (rVSVΔG-ZEBOV-GP and Ad26.ZE-
BOV/MVA-BN-Filo) in adults and their persistence
until 1 year after vaccination and longer (middle/long
term). The second substudy, being conducted in Liberia,
is investigating viral shedding of the rVSVΔG-ZEBOV-
GP vaccine. The objective of this sub-study is to esti-
mate the proportion of children who shed vaccine virus
and to quantify the rVSVΔG-ZEBOV-GP vaccine shed-
ding in children (participants aged < 18 years) after the
prime and boost vaccinations. A third sub-study, asses-
sing the impact of malaria infections on immune re-
sponses to the vaccines, is planned to take place in
Sierra Leone and Guinea. A fourth sub-study, aiming to
identify multi-level determinants of participant retention
in the PREVAC trial to develop recommendations that
will benefit future clinical research in resource limited
settings affected by Ebola and other infectious diseases,
is planned to take place in the four countries.
Trial governance
The Partnership for Research on Ebola Vaccinations
(PREVAC) was established as an international consor-
tium at the end of the West-African outbreak in 2015 to
focus on Ebola research activities and to prevent or re-
spond effectively to the next potential Ebola outbreak.
The consortium includes research and academic institu-
tions (the French Institute for Health and Medical Re-
search [Inserm], the London School of Hygiene &
Tropical Medicine [LSHTM], the US National Institutes
of Health [NIH], the Universities of Bordeaux and Min-
nesota), health authorities and scientists from four
Ebola-affected countries (Guinea, Liberia, Sierra Leone,
and Mali), non-governmental organizations (the Alliance
for International Medical Action and Leidos Biomedical
Research, Inc.), and pharmaceutical companies (MSD,
Janssen Vaccines & Prevention B.V., and Bavarian Nor-
dic). Members of the PREVAC study group conducting
the vaccine trial are listed in Additional file 1: Appendix
3.
Trial governance is detailed in Additional file 1: Ap-
pendix 4 - Figure 1. The trial is being conducted under
the direction of a Trial Steering Committee (TSC),
which provides overall supervision for the trial on behalf
of the three sponsors (Inserm, LSHTM, NIH) and the
host countries. Members of the TSC (Additional file 1:
Appendix 4) are blinded to interim safety and immuno-
genicity results.
An Executive Committee is composed of representa-
tives of the sponsors and the coordinating investigator.
Ad hoc meetings of the executive committee are orga-
nized when a sponsor-level discussion is needed. The ex-
ecutive committee also has the final say in the event
consensus is not reached between TSC members.
A DSMB provides independent, expert oversight for
the trial and monitors accumulating safety data for
adults and children in each age group (1–4, 5–11, and
12–17 years) using reports provided by unblinded statis-
ticians from the University of Minnesota (Division of
Biostatistics, Minneapolis, USA).
The day-to-day operations and management of the
trial are coordinated by the Trial Management Team
(TMT). Daily monitoring of inclusions and retention
rates are carried out in the central database, and blind
reports are made available to the TMT via a secure web-
site by a blinded statistician from EUCLID/FCRIN Clin-
ical Trials Platform (Inserm/Univ Bordeaux, France). In
coordination with the sites, this close monitoring has
helped to achieve approximately the same number of
children in each age group and a gender balance in both
children and adults.
A centralized pharmacovigilance service has been im-
plemented for trial safety management. Adverse events
(AEs) occurring in enrolled participants are reported by
investigators as soon as they become aware of them. All
serious adverse events (SAEs) are reported to the spon-
sors immediately and no later than 24 h after the investi-
gator becomes aware of them. The medical officer (MO)
responsible for pharmacovigilance firsts performs a par-
tial unblinding of a potential suspected unexpected ser-
ious adverse reaction (SUSAR) to assess whether the
SAR is unexpected for either product. If the event is un-
expected for the product arm assigned (vaccine or
matched placebo), the MO asks to be fully unblinded to
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determine whether the participant received active vac-
cine or placebo. This full unblinding is also performed
via the web-based unblinding application monitored by
the University of Minnesota. All SUSARs or other new
safety data that would constitute new information for
competent authorities are reported to the DSMB. The
DSMB may pause enrolment in the event of vaccine-
related deaths or SAEs that are considered vaccine-
related. The DSMB may also pause enrolment or request
that participants be notified if there is an increased fre-
quency of unanticipated adverse effects.
Ethical and regulatory aspects
During the enrollment process, there was widespread
communication with local communities about the trial.
Potential participants joined a detailed group informa-
tion session prior to an individual session that included
the signing of an informed consent form if they agreed
to enroll. A flip chart describing the study was used to
ensure that illiterate volunteers and minors understood
the study requirements and risks and benefits in the
presence of an impartial witness. In Liberia and Sierra
Leone, minors aged 7–17 years signed an informed
assent form after their parents/guardian provided con-
sent for their participation in the study. Assent was not
required in either Guinea or Mali. Minors who declined
participation in the study after reviewing the assent ma-
terials were not enrolled even if their parent(s) or legal
guardian consented to their participation.
The study protocol, the informed consent and assent
forms (Additional file 1: Appendix 5), including partici-
pants’ information materials, were approved by ethics
committees of the sponsors (INSERM IRB 00003888,
LSHTM) and the implementing countries (Guinea,
Liberia, Mali, and Sierra Leone) before each version of
the protocol was implemented. NIH established an insti-
tutional reliance agreement with INSERM to rely upon
the INSERM ethics committee. The study is registered
at www.ClinicalTrials.gov (NCT02876328) and in the
Pan African Clinical Trials Registry (PACT
R201712002760250).
The data of this trial will be disseminated through na-
tional and international conferences and peer-reviewed
publications.
Social mobilization
Community-level social mobilization activities were de-
veloped in each site to engage local populations in inter-
ventional research and thus facilitate study enrollment.
Site-level procedures were also developed to support
participant retention, including visit incentives, partici-
pant tracking, digital and community-based outreach,
and use of community champions and community
mobilization techniques.
Results
Enrollment rate and retention
From April 2017 to December 2018, six sites in the four
collaborating countries (Guinea, Liberia, Mali, and Sierra
Leone) screened 5002 subjects and enrolled 4789 partici-
pants in one or other version of the study protocol
(Additional file 1: Appendix 6 - Figure 1-3, Appendix 7).
A total of 537 participants were enrolled in version 2.0
of the protocol from April to July 2017 in Guinea and
Liberia. A total of 1450 participants were enrolled in ver-
sion 3.0 of the protocol from July 2017 to March 2018
in Guinea and Liberia. Enrollment in version 4.0 oc-
curred over a period of eight months (April to December
2018) with a total of 2802 participants enrolling in the
six sites in the four countries, including 1401 children
with an equal distribution between the three age groups.
An average of 35.8, 41.4, and 79.2 participants per week
were enrolled in version 2.0, 3.0, and 4.0 respectively.
For protocol version 4.0, the proportion of visits
attended at M12 was 95.8% whilst for protocol versions
2.0 and 3.0, it was 96.1% and 97.1% respectively.
Baseline characteristics
The baseline characteristics of the participants included
in all versions of the PREVAC trial are described in
Table 2. Overall, the median age was 18 years [IQR 11–
28] and females constituted 45.5% of the study popula-
tion. Of the 4789 participants, 2560 (53%) were adults
and 2229 (47%) were children. Those < 18 years included
549 (12%) aged 1 to 4 years, 750 (16%) aged 5 to 11
years, and 930 (19%) aged 12–17 years.
At baseline, 13 (0.3%) participants reported having
contact with someone with Ebola either recently or in
the past, while 5 (0.1%) participants reported that their
recent or past work involved contact with a living or
dead person with Ebola or with the bodily fluid from a
patient.
Among participants enrolled, the median weight at
baseline was 54 kg [IQR 31–65], while the median body
mass index (BMI) among participants aged ≥ 6 years was
20.7 [17.6–23.8] at baseline. Among children aged ≤ 5
years, the median mid upper arm circumference was 15
cm [36.4–36.8].
Baseline laboratory measurements
Biochemical and hematological baseline laboratory mea-
surements are presented pooled for versions 2.0, 3.0, and
4.0 in Tables 3 and 4 for females and males respectively.
Laboratory measurements are detailed by country in
Additional file 1: Appendix – Table 1.
Among 2560 adult participants who had an HIV test,
54 (2.1%) tested positive for HIV. All children enrolled
in the study were HIV negative at baseline. Both adults
and children were tested for syphilis at baseline and 45
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(0.9%) participants tested positive and were referred for
treatment (Table 2).
Preliminary data on antibody titers at baseline
Preliminary baseline antibody data were available for
23% (1090) of the study population. This sample repre-
sented the samples transferred to and processed at the
LIBR in Liberia before September 23, 2019. On the 1090
participants, 676 (62%) were from the Mambolo site, 414
(38%) were from Landreah.
At baseline, the median IgG antibody level against
EBOV was 72 enzyme-linked immunosorbent assay units
(EU) per milliliter (IQR, 50 to 116; 5th and 95th
percentiles, 33 to 330). A total of 2.4% of participants
had antibody titers of greater than 607 EU/mL; 11.7%
had titers greater than or equal to 200 EU/mL (Table 5).
These preliminary results indicate that antibody titers
prior to vaccination are similar for males (84.2 EU/mL)
and females (79.8) and may be higher in adolescent (86.9
EU/mL) and adults (83.7 EU/mL) compared to young
children (68.2 EU/mL in 1–4 years old and 78.4 in 5–11
years old) (Additional file 1: Appendix 8).
Discussion
The successful planning and conduct of this randomized
trial of three Ebola vaccine strategies involving six sites
Table 2 Baseline characteristics of the participants included in the PREVAC trial
Version 2.0 Version 3.0 Version 4.0 All versions
No. Pct. No. Pct. No. Pct. No. Pct.
Country
Guinea 263 49.0 1068 73.7 999 35.7 2330 48.7
Liberia 274 51.0 382 26.3 477 17.0 1133 23.7
Sierra Leone 0 0.0 0 0.0 708 25.3 708 14.8
Mali 0 0.0 0 0.0 618 22.1 618 12.9
Gender
Male 333 62.0 743 51.2 1536 54.8 2612 54.5
Female 204 38.0 707 48.8 1266 45.2 2177 45.5
Age
1–4 years 0 0.0 82 5.7 467 16.7 549 11.5
5–11 years 0 0.0 283 19.5 467 16.7 750 15.7
12–17 years 41 7.6 422 29.1 467 16.7 930 19.4
18–34 years 354 65.9 413 28.5 946 33.8 1713 35.8
35–54 years 114 21.2 187 12.9 368 13.1 669 14.0
≥ 55 years 28 5.2 63 4.3 87 3.1 178 3.7
Median (25th, 75th %) 26 (20–35) 17 (11–28) 18 (8–27) 18 (11–28)
Indicators of increased risk
Contact with case 4 0.7 7 0.5 2 0.1 13 0.3
Work entailing contact 3 0.6 1 0.1 1 0.1 5 0.1
Clinical examination
Median (25th, 75th %)
Weight (kg) 64 (57–71) 54 (33–65) 52 (25–63) 54 (31–65)
Height (cm) 167 (160–173) 159 (143–168) 158 (128–168) 160 (140–169)
BMI* 22.4 (20.4–25.4) 20.2 (17.1–23.6) 20.5 (17.2–23.6) 20.7 (17.6–23.8)
Arm circumference** (cm) 15.8 (15.0–16.4) 15.5 (14.6–16.2) 15.5 (14.6–16.2)
Body temperature (o C) 36.5 (36.4–36.7) 36.5 (36.4–36.7) 36.6 (36.4–36.8) 36.6 (36.4–36.8)
Infection test results
HIV positive 14 2.6 15 1.0 25 0.9 54 1.1
Syphilis positive 11 2.0 16 1.1 18 0.6 45 0.9
No. enrolled 537 1450 2802 4789
*Age 6 years or older
**Age 5 years or younger
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Table 3 Baseline laboratory measurements of female participants included in the PREVAC trial (pooled for versions 2.0, 3.0, and 4.0)
Baseline laboratory measurements: females
Age 18+ (n = 1118 ) Age 12–17 (n = 429) Age 5–11 (n = 353) Age 1–4 (n = 276 )
Mean SD Mean SD Mean SD Mean SD
Biochemistry
ALT (U/L) 10.9 10.6 9.3 7.3 11.7 11.8 13.8 38.2
AST (U/L) 14.2 9.6 14.9 6.7 20.7 11.6 28.9 30.6
Creatinine (mg/dl) 0.80 0.15 0.66 0.15 0.53 0.13 0.38 0.10
Potassium (mmol/L) 4.1 0.4 4.2 0.3 4.1 0.4 4.3 0.5
Hematology
White blood cells (x10³/μL) 6.1 2.1 6.2 1.8 7.0 1.9 8.9 2.7
Neutrophils (x10³/μL) 2.9 1.2 2.7 1.1 2.9 1.4 3.2 1.4
Lymphocytes (x10³/μL) 2.5 1.4 2.6 0.9 3.0 0.9 4.5 1.7
Eosinophils (x10³/μL) 0.21 0.26 0.26 0.37 0.35 0.43 0.39 0.64
Monocytes (x10³/μL) 0.46 0.18 0.52 0.20 0.60 0.22 0.77 0.34
Basophils (x10³/μL) 0.08 0.10 0.08 0.04 0.10 0.05 0.15 0.09
Hemoglobin (g/dl) 12.3 1.3 12.3 1.3 11.9 1.2 10.7 1.2
Hematocrit (%) 37.5 3.6 37.2 3.5 36.0 3.4 33.2 3.2
Platelets (x10³/μL) 264.2 71.7 288.4 76.4 321.4 87.2 394.3 111.0
Red blood cells (x106/μL) 4.5 0.5 4.6 0.5 4.6 0.5 4.6 0.5
Red cell distribution width (%) 13.3 1.6 13.3 1.6 13.6 1.6 14.9 2.3
Mean corpuscular volume (fL) 83.8 7.0 80.9 7.3 78.1 6.4 72.8 8.0
Lower limit of detection is imputed for undetectable results
Table 4 Baseline laboratory measurements of male participants included in the PREVAC trial (pooled for versions 2.0, 3.0, and 4.0)
Baseline laboratory measurements: males
Age 18+ (n = 1440 ) Age 12–17 (n = 501 ) Age 5–11 (n = 396) Age 1–4 (n = 273)
Mean SD Mean SD Mean SD Mean SD
Biochemistry
ALT (U/L) 15.5 28.9 13.8 22.3 12.8 14.5 12.3 16.0
AST (U/L) 19.8 22.3 20.9 17.0 21.9 11.6 30.2 27.3
Creatinine (mg/dl) 1.00 0.21 0.75 0.22 0.53 0.14 0.39 0.10
Potassium (mmol/L) 4.2 0.4 4.3 0.4 4.2 0.4 4.3 0.5
Hematology
White blood cells (x10³/μL) 5.4 1.5 5.9 1.6 7.3 3.4 9.0 3.0
Neutrophils (x10³/μL) 2.4 1.1 2.4 1.1 2.9 1.3 3.0 1.3
Lymphocytes (x10³/μL) 2.2 0.7 2.5 0.7 3.2 2.5 4.6 2.1
Eosinophils (x10³/μL) 0.30 0.55 0.39 0.50 0.54 0.81 0.43 0.53
Monocytes (x10³/μL) 0.44 0.16 0.53 0.20 0.60 0.25 0.82 0.33
Basophils (x10³/μL) 0.08 0.03 0.09 0.04 0.11 0.13 0.15 0.08
Hemoglobin (g/dl) 14.2 1.5 12.9 1.5 11.6 1.2 10.4 1.3
Hematocrit (%) 43.1 4.3 39.0 4.2 35.0 3.5 32.1 3.6
Platelets (x10³/μL) 233.1 67.7 270.6 79.3 309.2 89.6 409.5 139.6
Red blood cells (x106/μL) 5.1 0.6 4.9 0.5 4.5 0.5 4.5 0.6
Red cell distribution width (%) 13.1 1.4 13.4 1.6 13.7 1.5 15.4 2.1
Mean corpuscular volume (fL) 84.8 6.7 80.4 6.3 77.2 6.0 71.5 7.4
Lower limit of detection is imputed for undetectable results
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within four West African Countries, three sponsors, one
NGO, and two pharmaceutical companies is a milestone
in collaborative Ebola vaccine research. The results of
PREVAC will inform safety and characterize both short-
term and long-term immune responses for three vaccine
strategies for the prevention of Ebola virus disease in
adults and children.
Prior to the design and conduct of PREVAC, most
Ebola vaccine phase II trials did not involve children
[12]. The involvement of children aged 1–17 in PREV
AC is key in evaluating the safety profile of the different
candidate vaccines in children. Almost half (2229 out of
4789) of participants who enrolled in PREVAC were
children aged 1–17 years. Considering that the percent-
age of children who were infected with EVD during the
2014–2015 epidemic in West Africa was 16% and these
children had a higher case fatality rate than adults [13],
the results from this trial will provide important infor-
mation to guide the vaccination of children in future ep-
idemics such as the one ongoing in DRC where children
are being vaccinated.
Whether the different vaccination approaches are
able to confer durable antibody responses after vac-
cination remains an important question and currently
limited data exist to address this question. The PREV
AC and PREVAC-UP trials will evaluate the durability
of immune responses with follow-up of the partici-
pants up to 60 months after vaccination. These data
will provide important information when considering
a preventive vaccination strategy for at-risk popula-
tions, including health-care and front-line workers
who may face ongoing exposure to cases over re-
peated outbreaks.
The use of a placebo in a clinical trial of a vaccine
considered to be efficacious in preventing EVD would
be difficult to justify during an active outbreak. How-
ever, its use was considered ethical in the current
non-epidemic context in the four countries participat-
ing in the trial. Placebo controls are an important
strength of this trial for the evaluation of safety out-
comes. A provision was included in the design of
PREVAC that indicated that the use of placebos and
the study design would be reconsidered if Ebola
returned to these countries during the trial. With the
planned long-term follow-up, the same provision will
apply. Given the recent licensure of the rVSVΔG-
ZEBOV-GP by both the EMA and the FDA, it would
be unethical to conduct an efficacy trial with a pla-
cebo arm.
The inclusion of the two most promising vaccines was
also a strength of the trial. The opportunity to collabor-
ate with the respective companies producing the vaccine
and the use of pooled placebo arms were efficient and
appropriate given the urgency of the public health need.
There were efforts to achieve equal demographic dis-
tribution among participants. An enrollment monitoring
team was established to ensure that there was diversity
in the ages of children enrolled, especially during enroll-
ment into version 4.0 of the trial. This system allowed a
good representation of each age cohort in the trial as
was done in PREVAIL I [7].
The design of the trial had to evolve quickly over time
to adapt to emerging safety information and the realities
of vaccine production. The PREVAC trial began enroll-
ment with version 2.0 with only two arms and one vac-
cine strategy while awaiting additional safety
investigation on a Merck vaccine lot and the availability
of a new lot of the rVSVΔG-ZEBOV-GP vaccine. The 5-
arm design was split into two successive phases, version
3.0 (diluted rVSVΔG-ZEBOV-GP) and version 4.0 (un-
diluted rVSVΔG-ZEBOV-GP), because the lot release
potency of rVSVΔG-ZEBOV-GP vaccine was 9.4 × 107
pfu/mL, which, while within the pre-specified release
range of the manufacturer, was greater than the dose
Table 5 Preliminary baseline antibody data (based on a subset of samples of the PREVAC trial participants from version 2.0, 3.0 and
4.0 that were not randomly selected)









All children 413 81.3 68 (47, 116) 30, 451 54 (13.1%) 15 (3.6%)
1–4 years 44 68.2 56 (43, 90) 26, 227 4 (9.1%) 2 (4.5%)
5–11 years 162 78.4 68 (46, 119) 28, 351 21 (13.0%) 4 (2.5%)
12–17 years 207 86.9 71 (49, 117) 34, 470 29 (14.0%) 9 (4.3%)
All adults 677 83.7 74 (52, 114) 34, 317 74 (10.9%) 11 (1.6%)
18–25 years 392 86.0 75 (52, 122) 33, 335 45 (11.5%) 8 (2.0%)
26–45 years 205 78.7 69 (50, 103) 35, 269 19 (9.3%) 2 (1.0%)
46+ years 80 86.5 73 (54, 126) 37, 300 10 (12.5%) 1 (1.3%)
All ages 1090 82.8 72 (50, 116) 33, 330 128 (11.7%) 26 (2.4%)
*Geometric mean titer of antibody testing through 22 September 2019
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with which the investigators had experience in Liberia in
PREVAIL I [7]. Variation in the potency in live virus
vaccines is common. Vaccine manufacture and release
for potency is based upon defined specifications and al-
ways encompasses a range with a lower limit. The lower
limit is determined during development and is defined
by the lowest dose for which there is demonstrated effi-
cacy. The lower limit for potency must still be valid at
the end of shelf-life in order to ensure that the vaccine is
still efficacious until its defined expiry. Given this, the
initial potency of any given lot is typically considerably
higher than the nominal dose.
Prior to the conduct of PREVAC, only half the trial
sites had prior experience on mobilization and commu-
nity awareness programs for enrollment and retention of
participants in clinical trials. Community engagement is
pivotal to recruitment and retention of participants in
clinical trials [14, 15]. While establishing clinical trial
capacity in new sites and upgrading existing sites, com-
munity awareness was an integral component that led to
achievement of a high rate of enrollment of adults and
children in a short period of time and a very low drop-
out rate. At most sites, the number of eligible volunteers
willing to enroll exceeded the number of participants re-
quired. Based on our experience, the development of
plans for engaging the community will be an important
consideration in future studies carried out by our
partnership.
The implementation of a clinical trial such as PREV
AC builds and strengthens capacity in clinical research
for the personnel involved and physical infrastructure at
each site. These personnel have also been able to bring
their expertise to other African countries, for example
some of site staff went to DRC to strengthen the Ebola
clinical research capacity deployed to fight the current
epidemic. Such trials can also lead to better training pro-
grams for clinical researchers in African institutions.
In conclusion, the results of the PREVAC trial will ex-
tend our knowledge of the safety and long-term im-
munogenicity of the two most promising vaccines to
prevent Ebola.
Trial status
The recruitment of participants for this trial has been
finished, and the 1-year follow-up (primary outcome) of
the trial was completed by December 24, 2019. The 5-
year follow-up is planned to be completed in December
2023. The current version of the protocol is version 5.0
(October 3, 2019). This manuscript describing the study
protocol was submitted after all participants were in-
cluded in the different versions of the protocol. This was
done in order to be able to present all the versions and
to present the baseline characteristics of the participants
included in the PREVAC study.
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